New concepts in diastolic dysfunction and diastolic heart failure: Part II. Causal mechanisms and treatment

Circulation

Volumn 105, Issue 12, 2002, Pages 1503-1508

  Zile, Michael R ^a   Brutsaert, Dirk L ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Diastole; Heart failure; Systole

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN HEXETIL; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DRUG; MCC 135; NEUROHORMONE; NIFEDIPINE; NITRIC ACID DERIVATIVE; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; UNCLASSIFIED DRUG; VERAPAMIL;

ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONSERVATIVE TREATMENT; DIASTOLE; DIASTOLIC BLOOD PRESSURE; EXTRACELLULAR MATRIX; HEART FAILURE; HEART MUSCLE CELL; HUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; TREATMENT PLANNING;

ANIMALS; DIASTOLE; ENDOTHELIUM, VASCULAR; EXTRACELLULAR MATRIX; HEART FAILURE, CONGESTIVE; HUMANS; MYOCARDIUM; PRACTICE GUIDELINES; RANDOMIZED CONTROLLED TRIALS;

EID: 0037177171     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/hc1202.105290     Document Type: Article

References (53)

1. New concepts in diastolic dysfunction and diastolic heart failure: Part I. Diagnosis, prognosis, and measurements of diastolic function
2. Cellular mechanisms underlying left ventricular diastolic dysfunction
3. Energetics of the normal and failing human heart: Focus on the creatine kinase reaction
4. Regulatory proteins and diastolic relaxation
5. Chemomechanical energy transduction in the failing heart
6. Failure to maintain a low ADP concentration impairs diastolic function in hypertrophied rat hearts
7. Cardiocyte cytoskeleton in hypertrophied myocardium
8. The cytoskeleton and related proteins in the human failure heart
9. Beneficial effects of nitric oxide on cardiac diastolic function: "The flip side of the coin"
10. Differential effects of natriuretic peptides and NO on LV function in heart failure and normal dogs
11. Pathological hypertrophy and cardiac interstitium: Fibrosis and renin-angiotensin-aldosterone system
12. Structural remodeling in hypertensive heart disease and the role of hormones
13. The collagen matrix of the heart
14. Cardiac interstitium in health and disease: The fibrillar collagen network
15. Factors influencing diastolic function: Possible role of the extracellular matrix
16. Integrins and the myocardium
17. Myocardial matrix degradation and metaltoproteinase activation in the failing heart: A potential therapeutic target
18. Differential effects of pressure or volume overload on myocardial MMP levels and inhibitory control
19. Matrix metalloproteinase inhibition during the development of congestive heart failure: Effects on left ventricular dimensions and function
20. Alterations in the determinants of diastolic suction during pacing tachycardia
21. Differential expression of cardiac tifin isoforms and modulation of cellular stiffness
22. Cytoskeletal mechanics in pressure overload cardiac hypertrophy
23. Gel stretch method: A new method to measure constitutive properties of cardiac muscle cells
24. Constitutive properties of adult mammalian cardiac muscle cells
25. Constitutive properties of hypertrophied myocardium: Cellular contributions to changes in myocardial stiffness and viscosity
26. Fibrillar collagen and myocardial stiffness in the intact hypertrophied rat left ventricle
27. Myocardial fibrosis and pathologic hypertrophy in the rat with renovascular hypertension
28. Influence of collagen network on left ventricular systolic and diastolic function in aortic valve disease
29. Normalization of diastolic dysfunction in aortic stenosis late after valve replacement
30. Inhibition of collagen cross-linking: Effects on fibrillar collagen and ventricular diastolic function
31. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease
32. Cardiac endothelium and myocardial function
33. Management of left ventricular diastolic dysfunction
34. Diastolic heart failure: Diagnosis and treatment
35. Diastolic heart failure
36. Diminished contractile response to increased heart rate in intact human left ventricular hypertrophy: Systolic versus diastolic determinants
37. Altered myocardial force-frequency relation in human heart failure
38. Diastolic dysfunction in hypertrophic cardiomyopathy: Effect on active force generation during systole
39. Optimum heart rate of large failing hearts
40. Left ventricular hypertrophy and impaired diastolic filling in essential hypertension: Diastolic mechanisms for systolic dysfunction during exercise
41. Exercise intolerance in patients with heart failure and preserved left ventricular systolic function: Failure of the Frank-Starling mechanism
42. Abnormalities of diastolic function as a potential cause of exercise intolerance in chronic heart failure
43. Diastolic dysfunction as a cause of exercise intolerance
44. Hemodynamic loads and left ventricular diastolic function: Factors affecting the indices of isovolumetric and auxotonic relaxation
45. Verapamil-induced improvement in left ventricular filling and increased exercise tolerance in patients with hypertrophic cardiomyopathy: Short and long term results
46. Usefulness of verapamil for congestive heart failure associated with abnormal left ventricular diastolic filling and normal left ventricular systolic performance
47. Losartan improves exercise tolerance in patients with diastolic dysfunction and a hypertensive response to exercise
48. Beta adrenergic stimulation with isoproterenol enhances left ventricular diastolic performance in hypertrophic cardiomyopathy despite potentiation of myocardial ischemia: Comparison to rapid atrial pacing
49. Effects of ouabain and isoproterenol on left ventricular diastolic function during low-flow ischemia in isolated, blood-perfused rabbit hearts
50. Role of adrenoceptors and dopamine receptors in modulating left ventricular diastolic function
51. Improvement in indexes of diastolic performance in patients with congestive heart failure treated with milrinone
52. The effect of digoxin on mortality and morbidity in patients with heart failure